MarketPulse

checkpoint inhibitors

3 articles
BenzingaBenzinga··Nabaparna Bhattacharya

AIM ImmunoTech Surges 73% on Japanese Patent Victory for Cancer Therapy

AIM ImmunoTech ($AIMT) surged 73.66% after securing Japanese patent approval for Ampligen cancer therapy through 2039, strengthening its immuno-oncology portfolio.
AIMintellectual propertyorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

CTLA-4 Inhibitor Pipeline Expands With 50+ Candidates in Development Across 40+ Companies

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.
BMYCELGrAZNIVBIYAGEN+1FDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Checkpoint Inhibitor Market Analysis: 50+ Players Drive Immuno-Oncology Innovation Through 2026

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.
BMYCELGrKYKOYRNAZclinical trialscompetitive landscape